Starpharma Holdings Ltd (AU:SPL) — Market Cap & Net Worth
Market Cap & Net Worth: Starpharma Holdings Ltd (SPL)
Starpharma Holdings Ltd (AU:SPL) has a market capitalization of $206.99 Million (AU$292.55 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #16492 globally and #463 in its home market, demonstrating a 3.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Starpharma Holdings Ltd's stock price AU$0.70 by its total outstanding shares 420928435 (420.93 Million). Review Starpharma Holdings Ltd (SPL) financial obligations to assess the company's total debt and financial obligations.
Starpharma Holdings Ltd Market Cap History: 2015 to 2026
Starpharma Holdings Ltd's market capitalization history from 2015 to 2026. Data shows change from $223.38 Million to $206.99 Million (-0.33% CAGR).
Index Memberships
Starpharma Holdings Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.00 Trillion | 0.01% | #284 of 495 |
Weight: Starpharma Holdings Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Starpharma Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Starpharma Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.83x
Starpharma Holdings Ltd's market cap is 21.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $215.93 Million | $4.57 Million | -$21.29 Million | 47.21x | N/A |
| 2017 | $405.05 Million | $3.65 Million | -$15.22 Million | 111.06x | N/A |
| 2018 | $352.93 Million | $4.96 Million | -$10.29 Million | 71.20x | N/A |
| 2019 | $360.38 Million | $2.72 Million | -$14.25 Million | 132.49x | N/A |
| 2020 | $466.11 Million | $6.03 Million | -$14.68 Million | 77.26x | N/A |
| 2021 | $399.10 Million | $1.80 Million | -$19.73 Million | 221.97x | N/A |
| 2022 | $163.81 Million | $4.68 Million | -$16.15 Million | 34.99x | N/A |
| 2023 | $50.63 Million | $2.94 Million | -$15.64 Million | 17.23x | N/A |
| 2024 | $32.76 Million | $8.29 Million | -$8.16 Million | 3.95x | N/A |
| 2025 | $107.22 Million | $4.91 Million | -$9.99 Million | 21.83x | N/A |
Competitor Companies of SPL by Market Capitalization
Companies near Starpharma Holdings Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Starpharma Holdings Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Starpharma Holdings Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Starpharma Holdings Ltd's market cap moved from $223.38 Million to $ 206.99 Million, with a yearly change of -0.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$206.99 Million | +93.06% |
| 2025 | AU$107.22 Million | +227.27% |
| 2024 | AU$32.76 Million | -35.29% |
| 2023 | AU$50.63 Million | -69.09% |
| 2022 | AU$163.81 Million | -58.96% |
| 2021 | AU$399.10 Million | -14.38% |
| 2020 | AU$466.11 Million | +29.34% |
| 2019 | AU$360.38 Million | +2.11% |
| 2018 | AU$352.93 Million | -12.87% |
| 2017 | AU$405.05 Million | +87.59% |
| 2016 | AU$215.93 Million | -3.33% |
| 2015 | AU$223.38 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Starpharma Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $206.99 Million USD |
| MoneyControl | $206.99 Million USD |
| MarketWatch | $206.99 Million USD |
| marketcap.company | $206.99 Million USD |
| Reuters | $206.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more